Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent?

Finckh, A; Ciurea, A; Burlhart, L; Möller, B; Walker, UA; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2009). Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent? Annals of the rheumatic diseases, 69(2), pp. 387-393. London: BMJ Publishing Group 10.1136/ard.2008.105064

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Möller, Burkhard

ISSN:

0003-4967

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:11

Last Modified:

08 Jun 2016 10:52

Publisher DOI:

10.1136/ard.2008.105064

PubMed ID:

19416802

Web of Science ID:

000274047300014

URI:

https://boris.unibe.ch/id/eprint/31441 (FactScience: 195964)

Actions (login required)

Edit item Edit item
Provide Feedback